Bafrekalant

N/A

Report date: 2025/05/30 11:45:46
NME

Base Information

Drug NameBafrekalant
Drug Alias NameBAY-2586116
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPotassium channel subfamily K member 9 inhibitors
TargetsPotassium channel subfamily K member 9
Therapy Area/IndicationsSleep Apnea, Obstructive
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaGermanySwitzerland +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesFlinders UniversityBayer AGBayer Healthcare Company Ltd
Inactive CompaniesN/A
Active IndicationsSleep Apnea, Obstructive
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A